ADVFN - Advanced Financial Network.
HOME» AMEX » P » PLX Stock Price » PLX Stock News

Protalix Biotherapeutics Share News

 Protalix Biotherapeutics, Stock Price
PLX Stock Price
 Protalix Biotherapeutics, Stock Chart
PLX Stock Chart
 Protalix Biotherapeutics, Stock News
PLX Stock News
 Protalix Biotherapeutics, Company Information
PLX Company Information
 Protalix Biotherapeutics, Stock Trades
PLX Stock Trades

Pfizer To Pay Protalix Up To $115 Million In Gaucher's Deal

DOW JONES NEWSWIRES Pfizer Inc. (PFE) has reached an agreement to help Protalix Biotherapeutics Inc. (PLX) develop and commercialize a treatment for Gaucher's disease, getting up to $115 million in the process. Shares of Protalix jumped 10% to $10.85 premarket on the news, and Pfizer was up 0.8% to $18.32. The move comes as Genzyme Corp. (GENZ) in June had to suspend production of its Gaucher's treatment after a virus was found. The FDA in late August gave Protalix fast-track status, speeding up review of its product, which in October was reported to have met its primary goal in a late-stage trial. Gaucher's disease affects about one in 20,000 live births and causes a fatty substance to develop in cells primarily in the liver, spleen and bone marrow. Pfizer will pay Protalix $60 million up front and may make milestone payments of up to $55 million during development of the drug. The two companies will share future revenue and expenses for the development and commercialization of the drug, with Pfizer's share 60%. "Pfizer and Protalix expect to quickly deliver an alternative treatment for people suffering from Gaucher's disease," said Pfizer executive David Simmons. The company will receive exclusive worldwide licensing rights for the commercialization of the drug, while Protalix will keep its commercialization rights in Israel. -By Nathan Becker, Dow Jones Newswires; 212-416-2855; [email protected] Order free Annual Report for Genzyme Corporation Visit or call 1-888-301-0513

Stock News for Protalix Biotherapeutics (PLX)
02/23/201717:26:47Amended Statement of Ownership (sc 13g/a)
02/16/201716:32:38Current Report Filing (8-k)
02/15/201712:24:31Amended Statement of Ownership (sc 13g/a)
02/15/201712:21:51Statement of Ownership (sc 13g)
02/14/201718:12:28Statement of Ownership (sc 13g)
02/14/201718:11:33Current Report Filing (8-k)
02/14/201718:10:07Current Report Filing (8-k)
02/14/201712:02:49Amended Statement of Ownership (sc 13g/a)
02/14/201711:48:41Amended Statement of Ownership (sc 13g/a)
02/14/201710:27:37Amended Statement of Ownership (sc 13g/a)
02/01/201717:03:02Statement of Ownership (sc 13g)
01/09/201706:13:02Current Report Filing (8-k)
01/04/201710:56:33Amended Statement of Ownership (sc 13g/a)
01/03/201707:40:22Current Report Filing (8-k)
12/27/201607:39:52Current Report Filing (8-k)
12/23/201616:16:52Statement of Ownership (sc 13g)
12/14/201607:40:13Current Report Filing (8-k)
12/07/201617:28:25Current Report Filing (8-k)
12/06/201615:27:14Statement of Changes in Beneficial Ownership (4)
12/02/201606:04:28Current Report Filing (8-k)

Protalix Biotherapeutics and other American Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations